Home › Bladder Cancer › Texas
Bladder Cancer clinical trials in Texas
51 studies for Bladder Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston31 studies
- Dallas27 studies
- San Antonio13 studies
- Austin12 studies
- Killeen5 studies
- League City4 studies
- The Woodlands4 studies
- Irving3 studies
- Sugar Land3 studies
- Fort Worth3 studies
- Tyler3 studies
- Arlington3 studies
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03866382Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07061964A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Texas Oncology-Austin Central ( Site 0107), Austin
- Urology Austin, PLLC ( Site 0109), Austin
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06833073Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
- and 13 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- and 5 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07206225A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Dallas Fort Worth, Fort Worth
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478DESTINY-PANTUMOUR04
- Research Site, Dallas
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- USO-Texas Oncology-Central/South Texas, Austin
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
- UT Southwestern Medical Center, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06394570A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Texas Oncology, Austin
- Texas Oncology - Northeast Texas, Tyler
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07566156A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- Urology Austin, PLLC ( Site 0008), Austin
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07222488A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07090499Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- UPNT Research Institute, LLC, Arlington
- Urology Austin, PLLC (Urology America), Austin
- Urology Clinics of North Texas, PLLC, Dallas
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06567743A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
- University of Texas Southwestern Medical Center, Dallas
- University of Texas Health Science Center at San Antonio, San Antonio
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Aug 24, 2026 · NCT05825950Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Urology Partners of North Texas, Arlington
- Urology Austin, LLC, Austin
- Houston Metro Urology, Houston
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05951179Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
- Urology Partners of North Texas, Arlington
- Houston Metro Urology, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07480356Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Dallas
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07129993FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739Measuring Surgical Recovery After Radical Cystectomy
- University of Texas - Southwestern, Dallas
- University of Texas MD Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT03193970Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- MD Anderson in The Woodlands, Conroe
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07097142A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Urology Austin, Austin
- UT Southwestern Medical Center, Dallas
- Houston Metro Urology, Houston
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Texas Oncology - West Texas, Abilene
- Local Institution - 0187, Austin
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT07106762A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Baylor Scott and White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center - Temple, Temple
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Dallas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- NEXT Dallas, Dallas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07337525Predicting BCG Response
- University of Texas Southwestern, Dallas
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT04564781A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
- and 5 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Austin Urology Institute, Austin
- UT Southwestern Medical Center, Dallas
Recruiting
Ages 18 to 88 · All sexes · Updated Jul 2, 2026 · NCT06394869Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.